Richard O Ransom, 81Conway, SC

6407207, Jun 18, 2002

Nov 8, 1993

08/148708

Joseph A. Borkowski - Montclair NJ
John W. Hess - Westfield NJ
Catherine D. Strader - Verona NJ
Richard W. Ransom - New Britain PA

Merck Co., Inc. - Rahway NJ

C07K 14705

530350, 435 691, 536 235

The present invention is a cloned human BK-2 bradykinin receptor cloned from a human lung fibroblast cell line. A cDNA clone, also part of the instant invention, encodes a novel 364 amino acid protein (the BK-2 receptor) that has the characteristics of a seven transmembrane domain G-protein coupled receptor. The invention is used to express a BK-2 bradykinin receptor in a host mammalian cell to screen for pharmaceutical antagonists or agonists which bind to or interact with the BK-2 bradykinin receptor protein.

5204354, Apr 20, 1993

Feb 14, 1992

7/826726

Prasun K. Chakravarty - Edison NJ
E. M. Naylor - Scotch Plains NJ
Richard W. Ransom - New Britain PA

Merck & Co., Inc. - Rahway NJ

C07D23991
A61K 31505

514259

Substituted quinazolinones of the formula are useful as neurotensin antagonists. ##STR1##.

5718912, Feb 17, 1998

Oct 28, 1996

8/736705

Wayne J. Thomspon - Lansdale PA
Pierre Mallorga - Lansdale PA
Richard W. Ransom - New Britain PA
Ian M. Bell - Harleysville PA
Michael F. Sugrue - Blue Bell PA
Peter M. Munson - Harleysville PA

Merck & Co., Inc. - Rahway NJ

A61F 200
A01N 4340
A61K 31445

424427

This invention is concerned with novel 1-�cycloalkylpioeridin-4-yl!-2H benzimidazolones, their compositions and method of use. The novel compounds are selective muscarinic agonists of the m2 subtype with low activity at the m3 subtype. The compounds are effective for the treatment of glaucoma with fewer side effects than the pilocarpine therapy.

5288725, Feb 22, 1994

Oct 15, 1992

7/961589

Keith M. Witherup - Lansdale PA
Richard W. Ransom - New Britain PA
Sandor L. Varga - Harleysville PA
Steven M. Pitzenberger - Lansdale PA
Victor J. Lotti - Harleysville PA
William J. Lumma - Pennsburg PA

Merck & Co., Inc. - Rahway NJ

C07D47104
A61K 3144

514292

A pyrroloquinoline compound of the following formula is disclosed: ##STR1## wherein H, C. sub. 1-6 alkyl, R. sup. 1 is: ##STR2## wherein R is H, C. sub. 1-10 alkyl, or C. sub. 1-6 alkyloxycarbonyl; R. sup. 2 is: H, C. sub. 1-6 alkyl, ##STR3## wherein R. sup. 5 is C. sub. 1-10 alkyl, aryl, or aryl C. sub. 1-10 alkyl; R. sup. 3 is: (CH. sub. 2). sub. n NHR wherein R is H, C. sub. 1-6 alkyl, or C. sub. 1-6 alkyloxycarbonyl; ##STR4## R. sup. 4 is: H, C. sub. 1-6 alkyl, C. sub. 1-6 alkyloxycarbonyl, RCH. sub. 2 --, wherein R is H, C. sub. 1-6 alkyl or aryl, or ##STR5## X is O, or NR. sup. 6 wherein R. sup. 6 is equal to H or C. sub. 1-6 alkyl and n is an integer from 1-3. The compounds of the invention exhibit bradykinin antagonist activity as well as activity with. alpha.

5756508, May 26, 1998

Oct 28, 1996

8/736704

Wayne J. Thompson - Lansdale PA
Richard W. Ransom - New Britain PA
Pierre Mallorga - Lansdale PA
Michael F. Sugrue - Blue Bell PA

Merck & Co., Inc. - Rahway NJ

C07D21114
C07D23526
C07D23926
A61K 31415

514256

This invention is concerned with novel 1,3-dihydro-1-�1-(1-heteroarylpiperidin-4-yl)piperidin-4-yl!-2H-benzimidaz olones, derivatives thereof, their preparation, method of use and pharmaceutical compositions. These compounds are endowed with antimuscarinic activity and are useful in the treatment and/or prevention of myopia (commonly known as nearsightedness).